HyperiTab – Summary of Product Characteristics (SmPC) for healthcare professionals

1 NAME OF THE MEDICINAL PRODUCT

HyperiTab

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 313 mg of extract (as dry extract) from St

John’s Wort aerial parts (Hypericum perforatum L.) (equivalent to 1000 mg to

1500 mg of St. John’s Wort)

Extraction solvent: Methanol 80% v/v

Each film-coated tablet contains 13 mg of lactose

(See section 4.4. Special warnings and precautions for use)

For full list of excipients see section 6.1

3 PHARMACEUTICAL FORM

Clear dark purple-brown, mottled oval film-coated tablets.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

A traditional herbal medicinal product used to relieve the symptoms of slightly low mood and mild anxiety, based on traditional use only.

4.2 Posology and method of administration

For oral short-term use only

For adults and the elderly, take 1 - 2 tablets daily.

The tablets should be swallowed whole with a little water or other liquid. The tablets should not be chewed.

If symptoms worsen, or do not improve after 6 weeks, a doctor or qualified healthcare practitioner should be consulted.

This product is not recommended for children or adolescents under 18 years of age. (See Section 4.4 ‘Special warnings and precautions for use’)

4.3 Contraindications

Hypersensitivity to the active ingredient or any of the excipients.

Patients with known dermal photosensitivity or patients undergoing phototherapy or any photodiagnostic procedures.

This product should not be taken concomitantly with the medicines included in

Section 4.5. This is because St John’s Wort (Hypericum perforatum) has been shown to induce the cytochrome P450 isoenzymes CYP1A2, CYP2C9,

CYP2C19 and CYP3A4 as well as transport protein P-glycoprotein. This results in pharmacokinetic interactions with a large number of medicines leading to a possible decrease in the effectiveness of those medicines.

In addition, pharmacodynamic interactions have also been identified with antidepressants, particularly the SSRI antidepressants, and with the triptan group of medicines.

4.4 Special warnings and precautions for use

Do not exceed the stated dose.

If the condition worsens, or if symptoms persist for more than six weeks a doctor or qualified healthcare practitioner should be consulted.

The use of this product in children or adolescents under 18 years of age is not recommended because data are not sufficient and medical advice should be sought.

This product is intended for the relief of symptoms of slightly low mood and mild anxiety. Patients with signs and symptoms of depression should seek medical advice for appropriate treatment.

In very rare cases, particularly in fair-skinned persons, sun burn type reactions on skin areas exposed to strong sunlight may occur due to photosensitisation by St John’s Wort. Persons using this product should avoid excessive sunbathing or the use of sunbeds or solariums.

This product should be discontinued at least 10 days prior to elective surgery due to the potential for interactions with medicinal products used during general and regional anaesthesia (see Section 4.5).

Each film-coated tablet also contains 13 mg of lactose

Patients with rare hereditary problems of fructose intolerance, galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Substances in St John’s Wort (Hypericum perforatum) have been shown to induce the cytochrome P450 isoenzymes CYP1A2, CYP2C9, CYP2C19 and

CYP3A4 as well as transport protein P-glycoprotein. This results in pharmacokinetic interactions with a large number of medicines leading to a possible decrease in the effectiveness of those medicines. Clinically significant interactions have been reported with for example: warfarin, ciclosporin, HIV protease inhibitors, theophylline, digoxin, oral contraceptives and anticonvulsants.

The concomitant use of ciclosporin, tacrolimus for systemic use, Amprenavir, indinavir and other protease inhibitors, irinotecan and warfarin is contraindicated. Special care should be taken in case of concomitant use of all drug substances the metabolism of which is influenced by CYP1A2, CYP3A4,

CYP2C9, CYP2C19 or P-glycopprotein (e.g. amitriptyline, fexofenadine, benzodiazepines, methadone, simvastatin, digoxin, finasteride), because a reduction of plasma concentration is possible.

Users of oral contraceptives taking St John’s Wort (hypericum perforatum)

may experience intracyclic menstrual bleeding and risk of contraception failure is increased.

Clinically significant pharmacodynamic interactions have also been identified with the SSRI antidepressants and the triptan group of medicines used to treat migraines. Due to the increased risk of undesirable effects associated with these interactions this product should not be used concomitantly with these types of medicines.

Therefore, this product should not be taken concomitantly with the medicines included in the Table below.

4.6 Fertility, pregnancy and lactation

Safety of the product during pregnancy and lactation has not been established.

In the absence of sufficient data, the use during pregnancy and lactation is not

recommended.

Studies on the effects on fertility have not been performed.

4.7 Effects on ability to drive and use machines

No studies on the effect on the ability to drive and use machines have been

performed.

Deleted:

y

4.8 Undesirable effects

The following undesirable effects have been reported:

Gastrointestinal disorders (e.g. dyspepsia, anorexia, nausea, diarrhoea, constipation);

allergic skin reactions (e.g. rash, urticarial, pruritus); fatigue and restlessness. The frequency is not known.

Fair-skinned individuals may react with intensified sunburn-like symptoms under intense sunlight or strong ultra-violet (UV) irradiation.

Other adverse reactions that have been reported include, headaches, neuropathy, anxiety, dizziness and mania.

If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the

Google Play or Apple App Store

4.9 Overdose

After intake or up to 4.5g dry extract per day for 2 weeks and additionally 15g dry extract just before hospitalisation, seizures and confusion have been reported.

When a large overdose has occurred, phototoxic reactions may occur. The skin of the patient should be protected for one to two weeks from sunlight and other UV irradiation. Outdoor activities should be restricted, and clothes and/or sun block preparations used to protect the skin from sunlight.

Symptomatic and supportive measures should be taken as appropriate.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Herbal medicinal product for the treatment of depressive disorders.

ATC code: N06AP01

The active constituents of St John’s Wort have not been definitively established. However, the phloroglucinol constituent, hyperforin, and the hypericin group of constituents are thought to play an important role in its activity.

5.2 Pharmacokinetic properties

The active ingredients of St John’s Wort can interact with other medicinal agents in two ways. Firstly, active ingredients in St John’s Wort that themselves are metabolised in the liver by CYP3A4 isoenzyme, increase

(induce) the activity of this enzyme so that it accelerates the elimination of other medicinal agents that are degraded by the same pathway. This leads to a consequent reduction in the plasma concentration and effectiveness of these other substances. Secondly, the active ingredients in St John’s Wort, like other type SRI or SSRI medicinal agents with an antidepressant action, can raise the concentration of the serotonin in certain parts of the central nervous system so that this neurotransmitter can sometimes reach toxic levels, particularly when drugs containing St John’s Wort are combined with other antidepressants.

5.3 Preclinical safety data

Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Dicalcium phosphate anhydrous

Microcrystalline Cellulose PH102

Croscarmellose Sodium

Magnesium stearate

Hypromellose

Lactose

Colloidal anhydrous silica

6.2 Incompatibilities

Not applicable

6.3 Shelf life

18 months

6.4 Special precautions for storage

Do not store above 25º. Store in the original container.

6.5 Nature and contents of container

PVC/PVDC/Alu blisters in outer cardboard box

30 tablets

HDPE Bottle with Tapered Cap.

45 tablets

6.6 Special precautions for disposal

No special requirements

7 MARKETING AUTHORISATION HOLDER

Quest Vitamins Limited

Gooses Foot Estate, Kingstone,

Hereford, HR2 9HY, United Kingdom

Telephone: +44 121 359 0056

8 MARKETING AUTHORISATION NUMBER(S)

THR 12034/0027

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

04/03/2019

10 DATE OF REVISION OF THE TEXT

04/03/2019